Expertise in
3
conditions

Dr. Craig F. Laforce

Allergy and Immunology
2615 Lake Dr, Suite 301, 
Raleigh, NC 
Expertise in
3
conditions
2615 Lake Dr, Suite 301, 
Raleigh, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Craig Laforce is an Allergy and Immunologist in Raleigh, North Carolina. Dr. Laforce is highly rated in 3 conditions, according to our data. His top areas of expertise are Allergic Rhinitis, Asthma, Eosinophilic Asthma, and Chronic Eosinophilic Pneumonia.

His clinical research consists of co-authoring 36 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Allergy and Immunology
Licenses
Allergy & Immunology in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

2615 Lake Dr, Suite 301, Raleigh, NC 27607

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A Randomized, Double-blind, Placebo-controlled, Three-period Cross-over Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts (Maleate and Acetate) Delivered Via the Concept1 Inhalation Device in Patients With Asthma
A Randomized, Double-blind, Placebo-controlled, Three-period Cross-over Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts (Maleate and Acetate) Delivered Via the Concept1 Inhalation Device in Patients With Asthma
Enrollment Status: Completed
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: August 19, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label, Single-Center, Single-Dose, 3-Way Crossover Study of the Safety and Pharmacokinetics of Albuterol Administered by the Halix(TM) Albuterol Unit Dose Disposable Inhaler
An Open-label, Single-Center, Single-Dose, 3-Way Crossover Study of the Safety and Pharmacokinetics of Albuterol Administered by the Halix(TM) Albuterol Unit Dose Disposable Inhaler
Enrollment Status: Completed
Publish Date: January 30, 2019
Intervention Type: Drug
Study Phase: Phase 1
Cumulative Dose, 2-Way Crossover Study of the Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler Compared With MDI in Subjects With Asthma
Cumulative Dose, 2-Way Crossover Study of the Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler Compared With MDI in Subjects With Asthma
Enrollment Status: Completed
Publish Date: January 30, 2019
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: March 13, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

36 Total Publications

As-Needed Albuterol-Budesonide in Mild Asthma.
As-Needed Albuterol-Budesonide in Mild Asthma.
Journal: The New England journal of medicine
Published: May 19, 2025
Similar Doctors
Expertise in
6
conditions
Dr. Scott P. Commins
Allergy and Immunology
Expertise in
6
conditions
Dr. Scott P. Commins
Allergy and Immunology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (20.3 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Commins is an Allergy and Immunologist in Chapel Hill, North Carolina. Dr. Commins is highly rated in 6 conditions, according to our data. His top areas of expertise are Alpha-gal Syndrome (AGS), Anaphylaxis, Asthma, and Hives. Dr. Commins is currently accepting new patients.

Expertise in
6
conditions
Dr. Mary L. Markert
Allergy and Immunology | Pediatrics
Expertise in
6
conditions
Dr. Mary L. Markert
Allergy and Immunology | Pediatrics
2100 Erwin Rd, 
Durham, NC 
 (18.3 miles away)
919-620-4467
Languages Spoken:
English

Mary Markert is an Allergy and Immunologist and a Pediatrics provider in Durham, North Carolina. Dr. Markert is highly rated in 6 conditions, according to our data. Her top areas of expertise are Immune Defect due to Absence of Thymus, Pignata Guarino Syndrome, DiGeorge Syndrome, and Congenital Athymia.

Alan Aarons
Expertise in
16
conditions
Dr. Alan Aarons
Allergy and Immunology
Expertise in
16
conditions
Dr. Alan Aarons
Allergy and Immunology

Allergy Partners Of The Triangle - Cary

100 Parkway Office Ct, 
Cary, NC 
 (5.9 miles away)
919-859-8144
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alan Aarons is an Allergy and Immunologist in Cary, North Carolina. Dr. Aarons is highly rated in 16 conditions, according to our data. His top areas of expertise are Hives, Exercise-Induced Anaphylaxis (EIA), Anaphylaxis, and Serum Sickness.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Laforce's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile